Delcath Systems, Inc. (DCTH) announced on Tuesday encouraging results from an independent study on Percutaneous Hepatic Perfusion (PHP) in patients with Uveal melanoma.Conducted by researchers at Moffitt Cancer Center, the study involved 30 participants and compared Delcath’s HEPZATO KIT to immunotherapy and various liver-directed treatments.The results showed a median Overall Survival of 22.4 months for first-line therapy and 18.4 months for second-line therapy using the HEPZATO KIT.Moreover, the first-line application of the HEPZATO KIT resulted in a median Hepatic Progression-Free Survival of 17.6 months, significantly outperforming immunotherapy (8.8 months) and other therapies (9.2 months). Additionally, the first-line HEPZATO KIT demonstrated a median Progression-Free Survival of 15.4 months, again surpassing both immunotherapy and alternative treatments.Jonathan Zager, chief academic officer and director of Regional Therapies at Moffitt Cancer Center, emphasized that these findings highlight the critical role of melphalan/HDS in treating liver-dominant metastatic uveal melanoma.The material has been provided by InstaForex Company – www.instaforex.com
- J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer - September 14, 2024
- DIRECTV Reaches Agreement To Restore Disney Networks And Streaming Services - September 14, 2024
- Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint - September 14, 2024
